Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 6Glioblastoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Phase IB 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Mesonephric Gynecologic Cancer 1Melanoma 1Lung Neoplasms 1Low-Grade Serous Ovarian Cancer 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Endometrioid 1Brain Neoplasms 1Advanced Colorectal Cancer 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 31Pemetrexed 28Radiotherapy 22Bevacizumab 21Cisplatin 20Gemcitabine 18Paclitaxel 17Erlotinib Hydrochloride 15Docetaxel 12Gefitinib 8Nivolumab 6Mastectomy, Segmental 6Magnetic Resonance Spectroscopy 6pembrolizumab 5aflutinib 5Radiosurgery 5tislelizumab 4Vinorelbine 4Surgical Procedures, Operative 4Specimen Handling 4Sorafenib 4Platinum 4Metformin 4Biopsy 42-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 4sargramostim 3apatinib 3Taxes 3Cetuximab 3Anterior Temporal Lobectomy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma of Lung × defactinib × Clear all
NCT06495125 2026-04-06

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Emory University

Phase 2 Recruiting
50 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡